Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon-Reference-Cited by-全球学者库

Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon

Published:2015 Issue:3 Volume:5 Page:218-226
ISSN:1838-7640
Container-title:Theranostics
language:en
Short-container-title:Theranostics

Author:

Hou Feng-Qin,Song Liu-Wei,Yuan Quan,Fang Lin-Lin,Ge Sheng-Xiang,Zhang Jun,Sheng Ji-Fang,Xie Dong-Ying,Shang Jia,Wu Shu-Huan,Sun Yong-Tao,Wei Shao-Feng,Wang Mao-Rong,Wan Mo-Bin,Jia Ji-Dong,Luo Guang-Han,Tang Hong,Li Shu-Chen,Niu Jun-Qi,Zhou Wei-dong,Sun Li,Xia Ning-Shao,Wang Gui-Qiang

Publisher

Ivyspring International Publisher

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Medicine (miscellaneous)

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients;Scientific Reports;2024-01-17

2. A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues;Annals of Hepatology;2024-01

3. HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-α treated patients;2023-09-12

4. CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients;Journal of Medical Virology;2023-07

5. Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients;Infection and Drug Resistance;2023-06